According to the results of genetic and immunohistochemical analyses, we therefore subclassified these EGCs into three subtypes: the mutator/MSI-type (tumours with MSI-H and loss of hMLH1 expression), nine (8%) cases; suppressor/p53-type (tumour with strong p53 expression, or with LOH at D17S250), 49 (45%) cases and unclassified type, 52 (47%) cases (Figure 2 and Table 2). Here, TP53 is linked to neoplasm.